1. Vieta, E., Montes, J., Iborra, P., Mozos, A., Saez, C., & Benabarre, A. (2019). Management of asenapine treatment in clinical practice: Recommendations from a panel of experts. Revista de psiquiatria y salud mental, 12(3), 163-169. doi:10.1016/j.rpsm.2018.03.007
2. Citrome, L., Landbloom, R., Chang, C., & Earley, W. (2017, December 11). Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatric Disease and Treatment, 13, 2955-2963. doi:10.2147/NDT.S149376
3. Kementerian Kesehatan RI. (2018). Hasil Utama RISKESDAS 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan .
4. Balaraman, R., & Gandhi, H. (2010). Asenapine, a new sublingual atypical antipsychotic. Journal of Pharmacology & Pharmacotherapeutics, I(1), 60-61. doi:10.4103/0976-500X.64538
5. Reyad, A., & Mishriky, R. (2019, June). Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders. Psychiatria Danubina, 31(2), 157-161. doi:10.24869/psyd.2019.157.
6. Meltzer, H., Dritselis, A., Yasothan, U., & Kirkpatrick, P. (2009). Asenapine. National Revised Drug Discovery, 8, 843-844. doi:10.1038/nrd3027.
7. Citrome, L. (2009). Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. International Journal Clinical Practice, 1762-1784. doi:10.1111/j.1742-1241.2009.02228.
8. Ochi, S., Inoue, S., Yoshino, Y., Shimizu, H., Iga, J., & Ueno, S. (2019, November 20). Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report. Clin Psychopharmacol Neurosci, 17(4), 559-563. doi:10.9758/cpn.2019.17.4.559
9. Abruzzo, A., Cerchiara, T., Luppi, B., & Bigucci, F. (2019, September). Transdermal Delivery of Antipsychotics: Rationale and Current Status. CNS Drugs, 33(9), 849-865. doi:10.1007/s40263-019-00659-7
Facebook 
Masuk dengan Email
